

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Amended) A drug delivery composition consisting essentially of a coated HPMC capsule capable of containing [the] a drug, wherein the HPMC capsule [is provided with] comprises a single aqueous coating such that the drug is not released from the capsule in the stomach.
2. (Original) A drug delivery composition according to claim 1, wherein the HPMC capsule is provided with a coating such that the drug is predominately released from the capsule in the small intestine.
3. (Original) A drug delivery composition according to claim 1, wherein the HPMC capsule is provided with a coating such that the drug is predominately released from the capsule in the colon and/or terminal ileum.
4. (Amended) A drug delivery composition according to claim 2 wherein the coating [comprised] comprises a material which dissolves at a pH of 5.5 or above.
5. (Original) A drug delivery composition according to claim 3 wherein the coating comprises a material which dissolves at a pH 7 or above.
6. (Original) A drug delivery composition according to claim 2 wherein the coating comprises cellulose acetate trimellitate (CAT).
7. (Amended) A drug delivery composition according to claim 2 wherein the coating comprises hydroxypropylmethyl cellulose [phthalate] phthalate (HPMCP).
8. (Original) A drug delivery composition according to claim 2 wherein the coating comprises polyvinyl acetate phthalate (PVAP).
9. (Original) A drug delivery composition according to claim 2 wherein the coating comprises shellac.
10. (Previously Presented) A drug delivery composition according to claim 2 wherein the coating comprises a copolymer of methacrylic acid and methylmethacrylate.
11. (Original) A drug delivery composition according to claim 3 wherein the coating composition comprises a material which is redox-sensitive.
12. (Original) A drug delivery composition according to claim 3 wherein the coating composition comprises an azopolymer or a disulphide polymer.

6514-11

13. (Original) A drug delivery composition according to claim 3 wherein the coating composition comprises a material which is degraded by enzymes or bacteria present in the colon.

14. (Original) A drug delivery composition according to claim 3 wherein the coating composition comprises a copolymer of methacrylic acid and methylmethacrylate to which has been added during polymerisation the monomer methyl acrylate.

15. (Original) A drug delivery composition according to claim 3 wherein the coating composition comprises a cellulose ester.

16. (Original) A drug delivery composition according to claim 3 wherein the coating composition comprises polyvinyl acetate phthalate.

17. (Original) A drug delivery composition according to claim 2 wherein the coating is applied in the range of 5-15mg per cm<sup>2</sup> of capsule surface.

18. (Original) A drug delivery composition according to claim 3 wherein the coating is applied in the range 5-20mg per cm<sup>2</sup> of capsule surface.

19. (Previously Presented) A drug delivery composition according to claim 2 wherein the drug is one which is effective in the small intestine.

20. (Previously Presented) A drug delivery composition according to claim 1 wherein the drug is one which acts locally in the colon.

21. (Previously Presented) A drug delivery composition according to claim 1 wherein the coating is applied separately to empty HPMC capsule body and cap.

22. (Cancelled)

23. (Cancelled)

24. (Previously Presented) A drug delivery composition according to claim 1 wherein two equal HPMC capsule halves are filled with a caplet.

25. (Previously Presented) A drug delivery composition according to claim 24 wherein the coating is applied separately to equal empty HPMC capsule halves.

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

6514-11

29. (Previously Presented) A drug delivery composition according to claim 1 wherein the HPMC capsule is coated with a film which is non-dissolving at pH < 3 to 4 and dissolving at pH > 5.5.

30. (Previously Presented) A drug delivery composition according to claim 1 wherein the HPMC content of the capsule shell is in the range of from 10 to 90% by weight.

31. (Previously Presented) A drug delivery composition according to claim 1 wherein stomach resistant coating is applied to HPMC capsules having a sealing on the gap between capsule body and cap.

32. (Amended) A drug delivery composition [according to claim 24] consisting essentially of an HPMC capsule capable of containing a drug, wherein: (a) drug is not released from the capsule in the stomach; (b) one half of the capsule is enteric coated and the other half is colonic coated; (c) the enteric coating is at least one member selected from the group consisting of cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, shellac, and a copolymer of methacrylic acid and ethyl acrylate; and (d) the colonic coating is a member selected from the group consisting of azopolymers, disulphide polymers and amylose.

33. (Previously Presented) A drug delivery composition according to claim 24 wherein one half is coated with an insoluble polymer and the other half is enteric or colonic coated.